Identity
- Security key
- 18536
- Ticker
- MGTX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2018-06-08
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- MGTX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $1,200,219,327.36
- Shares outstanding (class)
- 92,609,516
- Shares outstanding (weighted)
- 92,609,516
- SIC
- 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 409
- Location
- NEW YORK, NY
- Homepage
- https://www.meiragtx.com
- Description
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.